US Stock MarketDetailed Quotes

BCAX Bicara Therapeutics

Watchlist
  • 23.820
  • +0.220+0.93%
Close Nov 8 16:00 ET
  • 23.820
  • 0.0000.00%
Post 16:00 ET
1.30BMarket Cap-17990P/E (TTM)

Bicara Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(FY)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-42.25%-45.63M
-32.08M
Net income from continuing operations
-37.36%-51.99M
---37.85M
Depreciation and amortization
90.00%19K
--10K
Other non cash items
--13.5M
----
Change In working capital
-294.46%-9.62M
--4.95M
-Change in prepaid assets
0.87%-914K
---922K
-Change in payables and accrued expense
-247.56%-8.66M
--5.87M
-Change in other current liabilities
---47K
--0
Cash from discontinued investing activities
Operating cash flow
-42.25%-45.63M
---32.08M
Investing cash flow
Cash flow from continuing investing activities
-205.21%-586K
-192K
Net PPE purchase and sale
-205.21%-586K
---192K
Cash from discontinued investing activities
Investing cash flow
-205.21%-586K
---192K
Financing cash flow
Cash flow from continuing financing activities
759.74%272.5M
31.7M
Net preferred stock issuance
763.63%272.35M
--31.54M
Proceeds from stock option exercised by employees
-6.88%149K
--160K
Cash from discontinued financing activities
Financing cash flow
759.74%272.5M
--31.7M
Net cash flow
Beginning cash position
-12.11%4.16M
--4.73M
Current changes in cash
39,590.75%226.28M
---573K
End cash Position
5,442.09%230.44M
--4.16M
Free cash flow
-43.22%-46.21M
---32.27M
Currency Unit
USD
USD
(FY)Dec 31, 2023(FY)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -42.25%-45.63M-32.08M
Net income from continuing operations -37.36%-51.99M---37.85M
Depreciation and amortization 90.00%19K--10K
Other non cash items --13.5M----
Change In working capital -294.46%-9.62M--4.95M
-Change in prepaid assets 0.87%-914K---922K
-Change in payables and accrued expense -247.56%-8.66M--5.87M
-Change in other current liabilities ---47K--0
Cash from discontinued investing activities
Operating cash flow -42.25%-45.63M---32.08M
Investing cash flow
Cash flow from continuing investing activities -205.21%-586K-192K
Net PPE purchase and sale -205.21%-586K---192K
Cash from discontinued investing activities
Investing cash flow -205.21%-586K---192K
Financing cash flow
Cash flow from continuing financing activities 759.74%272.5M31.7M
Net preferred stock issuance 763.63%272.35M--31.54M
Proceeds from stock option exercised by employees -6.88%149K--160K
Cash from discontinued financing activities
Financing cash flow 759.74%272.5M--31.7M
Net cash flow
Beginning cash position -12.11%4.16M--4.73M
Current changes in cash 39,590.75%226.28M---573K
End cash Position 5,442.09%230.44M--4.16M
Free cash flow -43.22%-46.21M---32.27M
Currency Unit USDUSD

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Concept Recent IPOs
Recent IPOs
Intraday+2.26%